Display options
Cite
Kotta S, Aldawsari HM, Badr-Eldin SM, et al. Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS. Pharmaceutics. 2021;13(9)doi: 10.3390/pharmaceutics13091347.
Kotta, S., Aldawsari, H. M., Badr-Eldin, S. M., Binmahfouz, L. S., Bakhaidar, R. B., Sreeharsha, N., Nair, A. B., & Ramnarayanan, C. (2021). Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS. Pharmaceutics, 13(9), . https://doi.org/10.3390/pharmaceutics13091347
Kotta, Sabna, et al. "Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS." Pharmaceutics vol. 13,9 (2021). doi: https://doi.org/10.3390/pharmaceutics13091347
Kotta S, Aldawsari HM, Badr-Eldin SM, Binmahfouz LS, Bakhaidar RB, Sreeharsha N, Nair AB, Ramnarayanan C. Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS. Pharmaceutics. 2021 Aug 27;13(9). doi: 10.3390/pharmaceutics13091347. PMID: 34575422; PMCID: PMC8471313.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2021 Aug 27;13(9). doi: 10.3390/pharmaceutics13091347.

Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS.

Pharmaceutics

Sabna Kotta, Hibah Mubarak Aldawsari, Shaimaa M Badr-Eldin, Lenah S Binmahfouz, Rana Bakur Bakhaidar, Nagaraja Sreeharsha, Anroop B Nair, Chandramouli Ramnarayanan

Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  2. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  3. Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  4. Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
  5. Department of Pharmaceutics, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore 560035, India.
  6. Department of Pharmaceutical Chemistry, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore 560035, India.

PMID: 34575422 PMCID: PMC8471313 DOI: 10.3390/pharmaceutics13091347

Abstract

Acute respiratory distress syndrome (ARDS), a catastrophic illness of multifactorial etiology, involves a rapid upsurge in inflammatory cytokines that leads to hypoxemic respiratory failure. Dexamethasone, a synthetic corticosteroid, mitigates the glucocorticoid-receptor-mediated inflammation and accelerates tissue homeostasis towards disease resolution. To minimize non-target organ side effects arising from frequent and chronic use of dexamethasone, we designed biodegradable, lung-targeted microspheres with sustained release profiles. Dexamethasone-loaded lipopolymeric microspheres of PLGA (Poly Lactic-co-Glycolic Acid) and DPPC (Dipalmitoylphosphatidylcholine) stabilized with vitamin E TPGS (D-α-tocopheryl polyethylene glycol succinate) were prepared by a single emulsion technique that had a mean diameter of 8.83 ± 0.32 μm and were spherical in shape as revealed from electron microscopy imaging. Pharmacokinetic and biodistribution patterns studied in the lungs, liver, and spleen of Wistar rats showed high selectivity and targeting efficiency for the lung tissue (

Keywords: ARDS; dexamethasone; lung inflammation; lung targeting; microspheres

References

  1. Colloids Surf B Biointerfaces. 2012 Feb 1;90:8-15 - PubMed
  2. BMJ. 2017 Apr 12;357:j1415 - PubMed
  3. J Drug Deliv. 2013;2013:374252 - PubMed
  4. Drug Des Devel Ther. 2018 Sep 18;12:3051-3060 - PubMed
  5. J Exp Med. 2006 Aug 7;203(8):1883-9 - PubMed
  6. Pharmaceutics. 2019 May 11;11(5): - PubMed
  7. Int J Pharm. 2016 Sep 25;511(2):1070-9 - PubMed
  8. AAPS PharmSciTech. 2005 Oct 06;6(2):E323-8 - PubMed
  9. Drug Des Devel Ther. 2019 Dec 27;13:4389-4403 - PubMed
  10. Arch Pharm Res. 2014 Mar;37(3):352-60 - PubMed
  11. JAMA. 2020 Jun 9;323(22):2329-2330 - PubMed
  12. Ochsner J. 2014 Summer;14(2):203-7 - PubMed
  13. Acta Pharm Sin B. 2021 May 7;: - PubMed
  14. Eur Surg Res. 2008;40(4):305-16 - PubMed
  15. Int J Pharm. 2005 Jan 31;289(1-2):63-7 - PubMed
  16. Int J Nanomedicine. 2012;7:6077-93 - PubMed
  17. Clin Ther. 2017 Nov;39(11):2216-2229 - PubMed
  18. Respir Care. 2017 Jan;62(1):113-122 - PubMed
  19. Molecules. 2019 Dec 13;24(24): - PubMed
  20. ACS Nano. 2020 Jun 23;14(6):6693-6706 - PubMed
  21. Pharm Res. 2003 Jul;20(7):1055-62 - PubMed
  22. J Surg Res. 2020 Feb;246:450-456 - PubMed
  23. Pharmaceutics. 2020 Dec 10;12(12): - PubMed
  24. J Clin Med. 2020 Jul 27;9(8): - PubMed
  25. Int J Mol Sci. 2014 Apr 08;15(4):5852-73 - PubMed
  26. Int J Pharm. 2018 Dec 1;552(1-2):241-250 - PubMed
  27. Front Mol Biosci. 2020 Nov 17;7:606393 - PubMed
  28. Drug Dev Res. 2018 Dec;79(8):373-382 - PubMed
  29. Pharmacol Rep. 2021 Jul 20;: - PubMed
  30. Ann Am Thorac Soc. 2015 May;12(5):765-74 - PubMed
  31. Nanomaterials (Basel). 2020 Jan 21;10(2): - PubMed
  32. Lancet Respir Med. 2020 Mar;8(3):267-276 - PubMed
  33. Adv Drug Deliv Rev. 1995 Sep;16(2-3):215-233 - PubMed
  34. Med J Aust. 2020 Jul;213(2):54-56.e1 - PubMed
  35. Drug Deliv. 2016 May;23(4):1282-90 - PubMed
  36. AAPS PharmSciTech. 2018 Oct;19(7):3085-3096 - PubMed
  37. Drug Des Devel Ther. 2015 Jan 23;9:273-82 - PubMed
  38. Pharmaceutics. 2021 Apr 09;13(4): - PubMed
  39. J Pers Med. 2021 Jun 15;11(6): - PubMed
  40. J Control Release. 1998 Feb 12;51(2-3):143-52 - PubMed
  41. Pharm Res. 2018 Feb 05;35(2):43 - PubMed

Publication Types

Grant support